Home » Medical Devices » Liraglutide Injection Market

Liraglutide Injection Market By Type (Type I, Type II) By Application (Hypoglycemic, Weight Loss, Others) – Growth, Future Prospects & Competitive Analysis, 2016 – 2028

Summary
Table Of Content

About this report

The global liraglutide injection market report explores the critical analysis of the liraglutide injection industry using key parameters. The report consists of investment strategies, the need for investments in the liraglutide injection industry, and the multiple benefits for investors. Importantly, this report sets out major changes in the global technical regulations for the liraglutide injection industry and how economic and non-economic barriers are helping the market grow. Moreover, the report analyses the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, and Tornado analysis. Key technological developments and other analyses include Porter’s five forces analysis, PESTEL analysis, value chain analysis, etc.

REPORT ATTRIBUTE	DETAILS
Liraglutide Injection Market by Volume	Yes
Liraglutide Injection Market by Value	Yes
Liraglutide Injection Market, Tornado Analysis	Yes
Liraglutide Injection Market, STAR Analysis	Yes
Liraglutide Injection Market, SRC Analysis	Yes
Liraglutide Injection Market, Import-Export Data	Yes (On Demand)
Liraglutide Injection Market Pricing Analysis	Yes (On Demand)
Liraglutide Injection Market Segment Analysis	By Type (Type I and Type II) By Application (Hypoglycemic, Weight Loss, and Others)
Liraglutide Injection Market, Regional Analysis	North America (the US and Canada) Europe (Germany, UK, France, Italy, Spain, and the Rest of Europe) Asia Pacific (China, India, Japan, South Korea, South East Asia, and the Rest of Asia Pacific) Latin America (Brazil, Mexico, and the Rest of Latin America) Middle East and Africa (GCC Countries, South Africa, and the Rest of the Middle East and Africa)
Liraglutide Injection Market Key Companies	Novo Nordisk, Abbott Ltd, Reddy’s Laboratories, Cipla, Senova Technology Co. Ltd, Shandong Octagon Chemicals Ltd, Apino Pharma Co. Ltd, Bachem Americas Inc, and Hybio Pharmaceutical
Liraglutide Injection Market Competitive Landscape	Market Share Analysis Competitive Benchmarking Key Players Market Positioning Geographical Presence Analysis Major Strategies Adopted

Key Highlights of the report

How are the major segments performing in the Liraglutide Injection Market?

In 2021, the type II segment led the global market and is expected to continue during the projection period. The use of liraglutide injection for type II diabetes is becoming more common around the world.
In 2021, the weight loss application segment held the largest global market share. Liraglutide injections are a popular weight-loss medication worldwide. It assists people in losing weight by reducing the amount of food they consume.

Which region dominated the liraglutide injection market?

North America dominated the global liraglutide injection market in 2021 and is expected to maintain its dominance throughout the forecast period. The rising geriatric population, soaring healthcare costs, geriatric population awareness, growing lifestyle-related diseases, and increasing costs of obesity and obesity-related diseases are all contributing factors to the region’s high demand for liraglutide injections. The demand for better and more affordable anti-obesity medications is driving the growth of the North American liraglutide injection market during the forecast period due to modern R&D facilities and novel therapeutic developments by major regional players.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

How is US Market Performing in the Liraglutide Injection Market?

The market for liraglutide injection in the United States is expected to expand significantly during the forecast period owing to the rising prevalence of obesity and diabetes. Novo Nordisk manufactures the diabetes medication liraglutide injection. Liraglutide injection is also widely used in the country to treat hypoglycemia. It helps to keep blood sugar levels within normal ranges by increasing pancreatic insulin release and decreasing liver sugar production. Besides, as people become more aware of the dangers of obesity, there is a surge in concern about being overweight, leading to a shift in consumer preference for anti-obesity drugs like liraglutide injection, which is expected to show positive market growth during the forecast period. Novo Nordisk recently launched Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition in the United States.

What is the competitive environment of the liraglutide injection market?

The liraglutide injection market is highly consolidated, with major manufacturers holding a global presence, including Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. Liraglutide formulation belongs to the GLP-1 agonist class of drugs. The GLP-1s are currently unavailable in generic form as they are a patent-protected product. Human glucagon-like peptide-1 is an analog found in liraglutide (GLP-1). It is classified as a GLP-1 receptor agonist and is 97% homologous to the native GLP-1 by modifying arginine for lysine at position 34. It received FDA approval for type 2 diabetes management in January 2010 and is now the sole property of Novo Nordisk A/S. Liraglutide is marketed as Victoza in the United States, United Kingdom, India, UAE, Japan, Kuwait, Canada, Europe, Iran, and the Philippines. Saxenda is the brand name under which liraglutide is marketed in Switzerland, Indonesia, Australia, Iran, Canada, Israel, Brazil, the United Kingdom, and the United States. Saxenda and Victoza contain the same active ingredient, liraglutide, and should not be combined or used with other GLP-1 receptor agonist medications.

Executive Summary

How does the rising prevalence of diabetes play an important role in the liraglutide injection market?

Approximately 463 million adults populations are expected to have type 2 diabetes in 2019, according to the International Diabetes Federation (IDF). A combination of genetic and lifestyle disorders contributes to the progression of the disease. Three clinical factors, including increased insulin resistance, elevated hepatic glucose production, and decreased insulin secretion, are considered to contribute to the pathophysiology of type 2 diabetes. The rising incidence of diabetes, growing public awareness of diabetes and its complications, and the expanding need for innovative therapies for treating diabetes are the main factors propelling the growth of the global liraglutide injection sales market. Liraglutide injection helps with blood glucose control.

Liraglutide has been shown to lower the risk for nonfatal myocardial infarction, nonfatal stroke, and the first occurrence of cardiac mortality in subjects with elevated cardiovascular risk. Young adults worldwide are increasingly using tobacco, drinking alcohol, eating fast food, and leading sedentary lifestyles, which will further cause the obesity market to grow significantly in the upcoming years. According to the World Health Organization (WHO), obesity is expected to affect 13% of people worldwide. Additional clinical studies have demonstrated that the prevalence rates for men and women are 11% and 15%, respectively. The FDA recently approved liraglutide injection for adults with type II diabetes mellitus, either in combination with other diabetes medications or as standard treatment when dieting. Adults with chronic weight problems may also use liraglutide with a healthy diet and regular exercise. Liraglutide injections resulted in greater weight loss than other glucagon-like peptide analogs.

Which are the key investments by the liraglutide injection market players?

The existence of high unmet medical needs for obesity management therapeutic interventions, combined with increased R&D investments, is the primary factor driving the growth of the liraglutide injection industry. The major players in the liraglutide injection market heavily invest in new product approvals, acquisitions, collaborations, and partnerships to broaden their global market reach. For instance, Novo Nordisk A/S recently acquired six companies, four of which were acquired within the last five years. Novo Nordisk’s largest acquisition was Dicerna Pharmaceuticals in 2021 for USD 3.3 billion. Novo Nordisk A/S has made acquisitions in two nations and two different US states. Life science is the industry the company targets the most (100%).

Some major players in the liraglutide injection market are Novo Nordisk, Abbott Ltd, Reddy’s Laboratories, Cipla, Senova Technology Co. Ltd, Shandong Octagon Chemicals Ltd, Apino Pharma Co. Ltd, Bachem Americas Inc, and Hybio Pharmaceutical.

What are the Major Driving Factors for the Liraglutide Injection Market?

The growing prevalence of Type II diabetes around the world drives market expansion. Environmental and lifestyle changes brought about by industrialization and migration to urban areas from rural areas may significantly impact the global Type II diabetes pandemic. Type II diabetes is a devastating condition characterized by hyperglycemia caused by insulin resistance, impaired insulin secretion, or both. Increased demand for liraglutide injectable medicine to treat type II diabetes will drive global market growth in the coming years. Besides, gestational diabetes in women raises the risk of developing type II diabetes later in life. The rising prevalence of gestational diabetes among women is expected to propel the global liraglutide injection market growth during the forecast period.

What are the Major Risks for the Liraglutide Injection Market?

The serious side effects of liraglutide are expected to hamper global market growth. Gastroenteritis, low blood sugar, kidney diseases (kidney failure), severe allergic reactions, gallbladder issues, and kidney stones are typical side effects. Other potential side effects involve thyroid tumors, cancer, an increase in heart rate, and severe allergic reactions. The high cost of this liraglutide injection may also limit its market growth over the forecast period.

Which is the key application in the liraglutide injection market?

The weight loss segment is anticipated to grow the fastest during the forecast period. Liraglutide injections are a well-known weight-loss therapy all over the world. It helps individuals lose weight by limiting the amount of food they eat. Liraglutide injection may also promote increased calorie burn. This injection is commonly used to treat obesity and obesity-related conditions. Liraglutide injection also postpones the time the stomach is empty, slowing food digestion and absorption and lowering blood sugar levels after meals. Liraglutide Injection also suppresses appetite, which can aid in weight loss. It works by lowering your food intake and assisting your body in burning more fat. Injections of liraglutide can help type II diabetics further control their blood sugar levels.

How is the liraglutide injection market performing in regions?

The North American liraglutide injection market is expected to expand significantly during the forecast period. The rapidly increasing prevalence of type 2 diabetes is primarily driving the region’s liraglutide market growth. According to the American Diabetes Association (ADA), type 2 diabetes affects nearly 9% of the population in the United States. The USFDA’s supportive regulatory framework for the marketing and selling liraglutide injection also contributes to the expansion of the regional market.

Europe is the second-largest regional market for liraglutide injections. The growing prevalence of obesity in the region’s young population drives the region’s liraglutide injection product demand. The developed healthcare infrastructure and widespread public awareness of the efficacy of the treatment of liraglutide in controlling the prevalence of type II diabetes and obesity in the region are expected to make Europe the region with the fastest-growing region, mainly in the liraglutide market.

What is the regulatory landscape for the liraglutide injection market?

The FDA has approved the liraglutide injection as an adjunct treatment to diet and exercise for improving glycaemic control in adults with type II diabetes. The regulatory approval allows liraglutide injection to be used as a monotherapy, as a second-line treatment, and in combination with other oral diabetes medications and is credited with driving the market. Moreover, the efforts of liraglutide injection manufacturers to obtain regulatory approvals for new liraglutide products are expected to drive market growth throughout the forecast period. For instance, Novo Nordisk reported in December 2020 that the US FDA had approved a revised label for Saxenda (Liraglutide) injection of 3 mg for use in the treatment of obesity in adolescents (12-17 years) with body weight over 60 kg and an initial body mass index (BMI) equivalent to 30 kg/m2 or higher for adults, as a supplement to lower-calorie meals and increased physical activity.

What is the Market Size of the Liraglutide Injection value?

The global liraglutide injection market is anticipated to grow at a substantial CAGR of 9.3% in the upcoming years. The global liraglutide injection industry is estimated to be worth USD 4.4 billion in 2021 and is expected to be worth USD 7.5 billion by 2028.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

What are the major players planning for the future of the liraglutide injection market?

Key players are involved in the regulatory approval of new product formulations and the launch of newly developed products. Increased funding for liraglutide R&D initiatives is also expected to aid the future growth of the global liraglutide injection sales market. Moreover, growing awareness of various weight-control drugs for treating obesity, combined with technological advancement, further drives the global market growth. The formulations of drugs that act as Glucagon-like peptide-1 receptor agonists have undergone several modifications owing to increased technological development. Players are attempting to introduce new uses for liraglutide injection, including the management of obesity. For instance, AstraZeneca’s once-weekly injectable suspension, Bydureon BCise (Liraglutide extended-release), was regulatory approved in July 2021 for the treatment of type 2 diabetes (T2D) to enhance glycaemic control in pediatric patients (10 to 17 years).

Segmentation of Global Liraglutide Injection Market –

Global Liraglutide Injection Market – By Type

Type I
Type II

Global Liraglutide Injection Market – By Application

Hypoglycemic
Weight Loss
Others

Global Liraglutide Injection Market – By Region

North America
- US
- Canada
Europe
- Germany
- France
- UK.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Liraglutide Injection Market
2.2. Global Liraglutide Injection Market, By Type
2.3. Global Liraglutide Injection Market, By Application
2.4. Global Liraglutide Injection Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Liraglutide Injection Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Market Drivers
3.2.3. Market Restraints
3.2.4. Market Opportunities
3.2.5. Major Industry Challenges
3.3. Attractive Investment Proposition,2021
3.3.1. Type
3.3.2. Application
3.3.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Value Chain Analysis
4.4. Technology Analysis
4.5. Marketing Strategy Analysis
4.5.1. Direct Marketing
4.5.2. Indirect Marketing
4.5.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2021
5.1. Company Market Share of Key Players, 2021
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. COVID-19 Impact Analysis
6.1. Global Liraglutide Injection Market Pre Vs Post COVID-19, 2019 – 2028
6.2. Impact on Import & Export
6.3. Impact on Demand & Supply

7. Global Liraglutide Injection Market
7.1. Global Liraglutide Injection Market, by Type, 2016-2028(US$ Bn)
7.1.1. Overview
7.1.2. Global Liraglutide Injection Market, By Type, 2021 vs 2028 (in%)
7.1.3. Global Liraglutide Injection Market, By Type I, 2016-2028 (US$ Bn)
7.1.4. Global Liraglutide Injection Market, By Type II, 2016-2028 (US$ Bn)
7.2. Global Liraglutide Injection Market, by Application, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Global Liraglutide Injection Market, By Application, 2021 vs 2028 (in%)
7.2.3. Global Liraglutide Injection Market, By Hypoglycemic, 2016-2028 (US$ Bn)
7.2.4. Global Liraglutide Injection Market, By Weight Loss, 2016-2028 (US$ Bn)
7.2.5. Global Liraglutide Injection Market, By Others, 2016-2028 (US$ Bn)

8. North America Liraglutide Injection Market Analysis
8.1. North America Liraglutide Injection Market, by Type, 2016-2028(US$ Bn)
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Liraglutide Injection Market, by Application, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
8.3.1. U.S.
8.3.1.1. U.S. Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.3.1.2. U.S. Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
8.3.1.3. U.S. Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
8.3.2. Canada
8.3.2.1. Canada Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.3.2.2. Canada Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
8.3.2.3. Canada Liraglutide Injection, By Application, 2016-2028 (US$ Bn)

9. Europe Liraglutide Injection Market Analysis
9.1. Europe Liraglutide Injection Market, by Type, 2016-2028(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Liraglutide Injection Market, by Application, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
9.3.1. Germany
9.3.1.1. Germany Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.1.2. Germany Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
9.3.1.3. Germany Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
9.3.2. France
9.3.2.1. France Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.2.2. France Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
9.3.2.3. France Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
9.3.3. UK
9.3.3.1. UK Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.3.2. UK Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
9.3.3.3. UK Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
9.3.4. Italy
9.3.4.1. Italy Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.4.2. Italy Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
9.3.4.3. Italy Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
9.3.5. Spain
9.3.5.1. Spain Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.5.2. Spain Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
9.3.5.3. Spain Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
9.3.6. Rest of Europe
9.3.6.1. Rest of Europe Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.3.6.2. Rest of Europe Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
9.3.6.3. Rest of Europe Liraglutide Injection, By Application, 2016-2028 (US$ Bn)

10. Asia Pacific Liraglutide Injection Market Analysis
10.1. Asia Pacific Liraglutide Injection Market, by Type, 2016-2028(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Liraglutide Injection Market, by Application, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
10.3.1. China
10.3.1.1. China Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.1.2. China Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
10.3.1.3. China Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
10.3.2. Japan
10.3.2.1. Japan Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.2.2. Japan Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
10.3.2.3. Japan Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
10.3.3. India
10.3.3.1. India Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.3.2. India Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
10.3.3.3. India Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
10.3.4. South Korea
10.3.4.1. South Korea Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.4.2. South Korea Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
10.3.4.3. South Korea Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
10.3.5. South-East Asia
10.3.5.1. South-East Asia Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.5.2. South-East Asia Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
10.3.5.3. South-East Asia Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
10.3.6. Rest of Asia Pacific
10.3.6.1. Rest of Asia Pacific Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.3.6.2. Rest of Asia Pacific Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
10.3.6.3. Rest of Asia Pacific Liraglutide Injection, By Application, 2016-2028 (US$ Bn)

11. Latin America Liraglutide Injection Market Analysis
11.1. Latin America Liraglutide Injection Market, by Type, 2016-2028(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Liraglutide Injection Market, by Application, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
11.3.1. Brazil
11.3.1.1. Brazil Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.3.1.2. Brazil Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
11.3.1.3. Brazil Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
11.3.2. Mexico
11.3.2.1. Mexico Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.3.2.2. Mexico Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
11.3.2.3. Mexico Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
11.3.3. Rest of Latin America
11.3.3.1. Rest of Latin America Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.3.3.2. Rest of Latin America Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
11.3.3.3. Rest of Latin America Liraglutide Injection, By Application, 2016-2028 (US$ Bn)

12. Middle East and Africa Liraglutide Injection Market Analysis
12.1. Middle East and Africa Liraglutide Injection Market, by Type, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Liraglutide Injection Market, by Application, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
12.3.1. GCC Countries
12.3.1.1. GCC Countries Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.3.1.2. GCC Countries Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
12.3.1.3. GCC Countries Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
12.3.2. South Africa
12.3.2.1. South Africa Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.3.2.2. South Africa Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
12.3.2.3. South Africa Liraglutide Injection, By Application, 2016-2028 (US$ Bn)
12.3.3. Rest of Middle East and Africa
12.3.3.1. Rest of Middle East and Africa Liraglutide Injection Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.3.3.2. Rest of Middle East and Africa Liraglutide Injection, By Type, 2016-2028 (US$ Bn)
12.3.3.3. Rest of Middle East and Africa Liraglutide Injection, By Application, 2016-2028 (US$ Bn)

13. Company Profiles
13.1. Novo Nordisk
13.1.1. Company Overview
13.1.2. Products/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2021)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Abbott Ltd
13.3. Reddy’s Laboratories
13.4. Cipla
13.5. Senova Technology Co. Ltd
13.6. Shandong Octagon Chemicals Ltd
13.7. Apino Pharma Co. Ltd
13.8. Bachem Americas Inc
13.9. Hybio Pharmaceutical

List of Figures

FIG. 1 Global Liraglutide Injection Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Liraglutide Injection Market Segmentation
FIG. 4 Global Liraglutide Injection Market, by Type, 2021 (US$ Bn)
FIG. 5 Global Liraglutide Injection Market, by Application, 2021 (US$ Bn)
FIG. 6 Global Liraglutide Injection Market, by Geography, 2021 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Type, 2021
FIG. 8 Attractive Investment Proposition, by Application, 2021
FIG. 9 Attractive Investment Proposition, by Geography, 2021
FIG. 10 Global Market Share Analysis of Key Liraglutide Injection Market Manufacturers, 2021
FIG. 11 Global Market Positioning of Key Liraglutide Injection Market Manufacturers, 2021
FIG. 12 Global Liraglutide Injection Market Value Contribution, By Type, 2021 & 2028 (Value %)
FIG. 13 Global Liraglutide Injection Market, by Type I, Value, 2016-2028 (US$ Bn)
FIG. 14 Global Liraglutide Injection Market, by Type II, Value, 2016-2028 (US$ Bn)
FIG. 15 Global Liraglutide Injection Market Value Contribution, By Application, 2021 & 2028 (Value %)
FIG. 16 Global Liraglutide Injection Market, by Hypoglycemic, Value, 2016-2028 (US$ Bn)
FIG. 17 Global Liraglutide Injection Market, by Weight Loss, Value, 2016-2028 (US$ Bn)
FIG. 18 Global Liraglutide Injection Market, by Others, Value, 2016-2028 (US$ Bn)
FIG. 19 U.S. Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 20 Canada Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 21 Germany Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 22 France Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 23 U.K. Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 24 Italy Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 25 Spain Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 26 Rest of Europe Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 27 China Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 28 Japan Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 29 India Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 30 South Korea Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 31 Southeast Asia Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 32 Rest of Asia Pacific Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 33 Latin America Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 34 Brazil Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 35 Mexico Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 36 Rest of Latin America Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 37 Middle East & Africa Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 38 GCC Countries Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 39 South Africa Liraglutide Injection Market, 2016-2028 (US$ Bn)
FIG. 40 Rest of Middle East and Africa Liraglutide Injection Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Liraglutide Injection Market
TABLE 2 Global Liraglutide Injection Market, by Competitive Benchmarking, 2021
TABLE 3 Global Liraglutide Injection Market, by Geographical Presence Analysis, 2021
TABLE 4 Global Liraglutide Injection Market, by Key Strategies Analysis, 2021
TABLE 5 Global Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 6 Global Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 7 Global Liraglutide Injection Market, by Geography, 2016-2028 (US$ Bn)
TABLE 8 North America Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 9 North America Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 10 North America Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
TABLE 11 US Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 12 US Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 13 Canada Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 14 Canada Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 15 Europe Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 16 Europe Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 17 Europe Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
TABLE 18 Germany Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 19 Germany Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 20 France Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 21 France Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 22 UK Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 23 UK Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 24 Italy Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 25 Italy Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 26 Spain Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 27 Spain Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 28 Rest of Europe Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 29 Rest of Europe Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 30 Asia Pacific Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 31 Asia Pacific Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 32 Asia Pacific Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
TABLE 33 China Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 34 China Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 35 Japan Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 36 Japan Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 37 India Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 38 India Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 39 South Korea Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 40 South Korea Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 41 South East Asia Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 42 South East Asia Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 43 Rest of Asia Pacific Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 44 Rest of Asia Pacific Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 45 Latin America Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 46 Latin America Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 47 Latin America Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
TABLE 48 Brazil Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 49 Brazil Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 50 Mexico Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 51 Mexico Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 52 Rest of Latin America Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 53 Rest of Latin America Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 54 Middle East and Africa Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 55 Middle East and Africa Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 56 Middle East and Africa Liraglutide Injection Market, by Country, 2016-2028 (US$ Bn)
TABLE 57 GCC Countries Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 58 GCC Countries Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 59 South Africa Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 60 South Africa Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)
TABLE 61 Rest of Middle East and Africa Liraglutide Injection Market, by Type, 2016-2028 (US$ Bn)
TABLE 62 Rest of Middle East and Africa Liraglutide Injection Market, by Application, 2016-2028 (US$ Bn)

Frequently asked questions

How does COVID-19 impact the global liraglutide injection market?

The COVID-19 pandemic positively impacted the global liraglutide injection market. In patients with COVID-19, diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes, including a higher risk of terminal illness or death. Liraglutide, like glucagon, is a peptide1 (GLP1) receptor, an agonist. As a result, GLP-1RAs have been identified as potential candidates for treating COVID-19 infection patients with or without type 2 diabetes, and they are excellent antidiabetic (glucose-low

Which is the leading region of the market for liraglutide injection?

North America accounted for the most heightened share in the global liraglutide injection market.

What are the key drivers for the growth of the liraglutide injection market?

The rising prevalence of type II diabetes, the growing geriatric population, and the increasing preference for weight-loss therapies are driving the growth of the global liraglutide injection market.

Which is the major liraglutide injection market segment by type?

The type II segment had a major share in the global market in 2021.

Which is the major liraglutide injection market segment by application?

The weight loss segment had a major share in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –